Key result
Plasma I-FABP levels were significantly elevated in patients with treated inflammatory bowel disease compared to healthy controls (P=0.000), with an AUC of 0.992 at a cutoff value of 4.65.
Why the study?
The study aimed to evaluate I-FABP levels in the follow-up of treated IBD patients compared to healthy control subjects.
Are I-FABP levels elevated in treated IBD patients compared to healthy controls?
Case-Control (n=90)
Are I-FABP levels elevated in treated IBD patients compared to healthy controls?
p-value: p=.000
I-FABP levels are significantly elevated in IBD patients compared to healthy controls, suggesting its utility as a biomarker for diagnosis and monitoring.
Background: Inflammatory bowel diseases (IBD) are a heterogeneous group of chronic relapsing diseases of the gastrointestinal tract. Intestinal fatty acid- binding proteins (I-FABP) defined as circulating or urinary markers of intestinal epithelial damage in patients with acute ischemia of the small bowel. Aim and objectives: to evaluate I-FABP level in the follow up of treated IBD patients compared to healthy control subjects. Subjects and methods: A case control study which included 60 patients was diagnosed IBD divided into equal two groups according to conventional or biological treatment and 30 healthy control subjects, aged from 16-70 years old. All investigations done accordingly plus I-FABP by Eliza. Results: In IBD females were 53% in conventional group. Laboratory findings were of statistical significant as regard higher Hb and lower number of platelets in biological group compared with conventional group, p value was .024 &.006 respectively. FABP levels were significantly elevated in studied IBD cases compared to control group, p value was .000 common complaint was abdominal pain in conventional group (70% versus 43.3% in biological group), while diarrhea was the most common in biological group (50% versus 20% in conventional group). Colonic left sided lesions in both groups. Cut off value of plasma FABP was 4.65 for all IBD patients with an AUC 98%, 77% and 0.992 respectively. Conclusion: I-FABP proved to be a useful biological marker in the diagnosis of IBD and can be used to monitor the progress of IBD.
No takes yet. Share an insight, caveat, or question.
El-Badawy et al. (2024) conducted a case-control in Inflammatory bowel diseases (IBD) (n=90). Inflammatory bowel disease (IBD) vs. Healthy controls was evaluated on I-FABP level (p=.000). Plasma I-FABP levels were significantly elevated in patients with treated inflammatory bowel disease compared to healthy controls (P=0.000), with an AUC of 0.992 at a cutoff value of 4.65.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: